• Issue
    2000
    5-99
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

Preface

  • Page: 5
  • First Published: 09 October 2008

Mutation of conserved aspartates affect maturation of presenilin 1 and presenilin 2 complexes

G. Yu,  F. Chen,  M. Nishimura,  H. Steiner,  A. Tandon,  T. Kawarai,  S. Arawaka,  A. Supala,  Y-Q. Song,  E. Rogaeva,  E. Holmes,  D. M. Zhang,  P. Milman,  P. Fraser,  C. Haass,  P. St George-Hyslop, 
  • Pages: 6-11
  • First Published: 02 January 2002

A pharmacogenomic approach to Alzheimer’s disease

R. Cacabelos,  A. Alvarez,  L. Fenández-Novoa,  V. R. M. Lombardi, 
  • Pages: 12-19
  • First Published: 02 January 2002

Magnetic resonance spectroscopy in Alzheimer's disease: focus on N-acetylaspartate

J. G. Chen,  H. C. Charles,  D. Barboriak,  P. M. Doraiswamy, 
  • Pages: 20-26
  • First Published: 02 January 2002

Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain†

W. Sihver,  B. Långström,  A. Nordberg, 
  • Pages: 27-33
  • First Published: 02 January 2002

Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types

C. Martin-Ruiz,  J. Court,  M. Lee,  M. Piggott,  M. Johnson,  C. Ballard,  R. Kalaria,  R. Perry,  E. Perry, 
  • Pages: 34-41
  • First Published: 02 January 2002

Classical Alzheimer features and cholinergic dysfunction: towards a unifying hypothesis?

A. Wevers,  B. Witter,  N. Moser,  L. Burghaus,  C. Banerjee,  O. K. Steinlein,  U. Schütz,  R. A. I. De Vos,  E. N. H. Jansen Steur,  J. Lindstrom,  H. Schröder, 
  • Pages: 42-48
  • First Published: 02 January 2002

An unusually glycosylated form of acetylcholinesterase is a CSF biomarker for Alzheimer's disease

J. Sáez-Valero*,  S. Mok Ss,  D. H. Small, 
  • Pages: 49-52
  • First Published: 02 January 2002

Acetylcholinesterase–amyloid-β-peptide interaction and Wnt signaling involvement in Aβ neurotoxicity

N. C. Inestrosa,  A. Alvarez,  J. Godoy,  A. Reyes,  G. V. De Ferrari, 
  • Pages: 53-59
  • First Published: 02 January 2002

Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease

D. K. Lahiri,  M. R. Farlow,  N. Hintz,  T. Utsuki,  N. H. Greig, 
  • Pages: 60-67
  • First Published: 02 January 2002

Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR

M. Samochocki,  M. Zerlin,  R. Jostock,  P. J. Groot Kormelink,  W.H. M. L. Luyten,  E. X. Albuquerque,  A. Maelicke, 
  • Pages: 68-73
  • First Published: 02 January 2002

The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics

N. H. Greig,  1 E. De Micheli,  1 H. W. Holloway,  1 Q.-S. Yu,  1 T. Utsuki,  1 T. A. Perry,  1 D. K. Ingram,  1 J. Deutsch,  2 D. Lahiri,  3 T. T. Soncrant, 
  • Pages: 74-84
  • First Published: 02 January 2002

Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial

P. S. Aisen, 
  • Pages: 85-89
  • First Published: 02 January 2002

Inhibiting the conversion of soluble amyloid-β peptide into abnormally folded amyloidogenic intermediates: relevance for Alzheimer's disease therapy

C. Soto*,  G. P. Saborio,  B. Permanne, 
  • Pages: 90-95
  • First Published: 02 January 2002

Immediate causes of death of demented and non-demented elderly

S. Kammoun,  G. Gold,  C. Bouras,  P. Giannakopoulos,  W. McGee,  F. Herrmann,  J-P. Michel, 
  • Pages: 96-99
  • First Published: 02 January 2002